Today marks an important milestone in our mission to transform diabetes care. I am excited to share that Glooko has acquired Monarch Medical Technologies, creators of the EndoTool® Glucose Management System.
With this acquisition, Glooko is positioned to become the only diabetes management company with the potential to connect the full continuum of care — from home to hospital and back again. By bringing together EndoTool’s proven inpatient insulin dosing technology with Glooko’s leading outpatient platform, we aim to create a future where care is seamless, safer, and more supportive for both people living with diabetes and healthcare providers.
For patients, this means fewer disruptions as they move between settings, reduced risk of dangerous glycemic events, and more confidence that their care is connected. For healthcare providers, it means access to tools that simplify complex insulin management, standardize protocols, and free up time to focus on what matters most, which is caring for people.
This step also sets the foundation for Glooko’s future: using data and AI to help clinicians anticipate risks earlier, personalize care at scale, and improve outcomes under value-based models. By aligning advanced technology with clinical guidelines and EHR workflows, we can help hospitals and health systems deliver higher-quality care while lowering costs.
Our mission has always been clear: to simplify diabetes management, strengthen connections across the care team, and improve lives. This acquisition represents an important stride toward that vision.
Together, we are building a future where diabetes care is more connected, proactive, and patient-centered than ever.
As I begin my new role as CEO of Glooko, I’m filled with both excitement and a deep sense of responsibility. Diabetes management has always been a deeply personal and complex journey for so many individuals, and the opportunity to lead a company dedicated to easing that burden is truly inspiring. This is more than just a new chapter for me; it’s a chance to make a real difference in the lives of people living with chronic conditions.
With the $100 million Series F financing, Glooko is in a strong position to accelerate our mission—simplifying diabetes management for patients, clinicians, and their care teams. As someone who has spent the majority of my career in healthcare technology and chronic condition management, I’m particularly excited to lead a company that is committed to easing the burden for patients with diabetes and their care teams. I’ve seen firsthand how data—while crucial—can become overwhelming, especially for those managing a condition like diabetes that requires constant monitoring. Whether it’s managing blood glucose levels, using insulin pumps, or trying to make sense of data from multiple apps, patients and clinicians are often left navigating a complex web of information. Particularly for physicians, sifting through and trying to make sense of that same sea of data to provide timely, effective care can be a daunting task.
At Glooko, we’re focused on tackling these challenges head-on. Our platform has the potential to provide actionable insights that streamline the management of chronic diseases like diabetes. We aim to simplify workflows, so that endocrinologists and diabetes care teams can focus on what matters most—to develop early intervention and care pathways that improve patient outcomes. We are also focused on expanding our work with our life sciences partners to enable clinical research and improve outcomes.
Our goal is clear: to make diabetes management easier for everyone—patients, clinicians, and partners. With the recent funding, we’re able to invest further in expanding our platform to support even more customers and to strengthen our integrations with electronic medical records (EMRs). This not only helps clinicians manage their workloads more effectively but also improves care coordination across the board.
I couldn’t be more excited to lead Glooko through this next phase of growth. We are at the forefront of changing how chronic diseases are managed by leveraging data to create new care pathways that make a real difference in patients’ lives. The possibilities for what we can achieve together are limitless, and I’m eager to work with our incredible team to bring these innovations to life.
This moment marks the beginning of an exciting journey, and I’m confident that, together, we’ll continue to set new standards for chronic condition management—making it easier, more efficient, and more effective for all.